GLP-1 agonist drug prescriptions surge 600% in U.S

Prescriptions for GLP-1 agonist drugs in the U.S. for weight loss and diabetes among ages 12-25 surged 594.4% from 2020 to 2023, with young women and girls seeing the largest increase. The study, published in JAMA, analyzed data from over 93% of U.S. retail pharmacies. Obesity and type 2 diabetes are rising among young people, with predictions of a 673% increase in type 2 diabetes cases by 2060.